Looking for a new opportunity? Our team is growing and looking for a research nurse to help us with our British Heart Foundation funded clinical trials in heart disease EdinUniCVS The University of Edinburgh elxw.fa.em3.oraclecloud.com/hcmUI/Candidat…

In patients who had myocardial infarction ruled out, those with intermediate troponin concentrations (5 ng/L - 99th centile) are 3× more likely to have CAD on CCTA than those with troponin <5 ng/L. jacc.org/doi/10.1016/j.… Nicholas Mills imagingmedsci EMERGE Dimitrios Doudesis, PhD

Fantastic to be at the GREAT-XIV international meeting after all the challenges of the past 18 months. Lots of interesting research and discussion ahead! #cardiology #troponin Nicholas Mills Dorien Kimenai Caelan Taggart Anda Bularga

What is the risk of myocarditis following COVID-19 vaccination or infection? Analysis from 38 million persons in the UK published today Nature Medicine Martina Patone Julia Hippisley-Cox Aziz Sheikh nature.com/articles/s4159…

#OriginalResearch: #DEMAND_MI 1st prospective study to undertake systematic cardiac imaging in patients with type 2 MI. Results show high prevalence of LV dysfunction & CAD Damini Dey imagingmedsci @marcdweck John Hung Anda Bularga Ryan Wereski Andrew Chapman ahajournals.org/doi/10.1161/CI…

The DEMAND-MI educational resource is now live. This is a CPD accredited tool for physicians with an interest in Type 2 MI, including detailed cases with investigation results and educational questions. Free to access after registration - example below #ACC22 #CardioEd #FOAMed

Long haul but finally arrived at #ACC22 in Washington DC! And presenting some work on risk stratifcation in type 2 MI. Keep your eyes peels for the moderated poster sessions tomorrow Hall C 13:30! Andrew Chapman Nicholas Mills KarlaM Anda Bularga Ryan Wereski Dorien Kimenai

Coronary or cardiac disease is common in type 2 myocardial infarction. Circulation Grateful to colleagues and mentors Andrew Chapman John Hung Marwa Daghem Stacey Schulberg Caelan Taggart imagingmedsci @MarcDweck #ProfNewby Nicholas Mills and the whole DEMAND-MI team! bit.ly/37hRxo0

Robotic PCI demo at #BCISACI was very smart - the system can cope with bifurcation lesions (max two wires, two balloons) and you can convert to manual in ~5 seconds in emergency. Future to minimise op radiation exposure?

Good to see there is consensus on some aspects of the diagnosis of type 2 myocardial infarction… Caelan Taggart presenting preliminary findings from our Delphi study #GREAT2022

The underlying aetiology of oxygen supply-demand imbalance among patients with type 2 myocardial infarction may provide useful prognostic information. @JamaNetworkOpen bit.ly/3O5VaNG Andrew Chapman Nicholas Mills Caelan Taggart Ryan Wereski Dorien Kimenai Atul Anand

Some highlights from day 1 of #ESCCongress with a stellar showing from the Edinburgh crew, great science and a lovely Women As One networking event to wrap up the day!@sjoshi_23 Anda Bularga Ken Lee Caelan Taggart Ryan Wereski @MarcDweck

Females with NSTE-ACS are not well risk assessed: GRACE 2.0 score was developed predominantly in males, whiel its sex-specific performance was unclear. iWe developed GRACE 3.0 that accounts for sex differences and reduces sex inequalities in risk stratification and management.

#OriginalResearch: Analysis from the #High-STEACS trial found that age alters the ability of cardiac #troponin to rule-in myocardial infarction with reduced performance in older patients Matthew Lowry Atul Anand #AHAJournals ahajrnls.org/3xskNCN

Excellent couple of days with colleagues in Uppsala - T2MI / TAVI / Biomarkers / Swedeheart and many cath labs !

Great time at #BCS2023. Great talks , clinical cases and always good to catch up with old friends.

Pleased to share the results of our latest study evaluating the role of "High-Sensitivity Cardiac Troponin for Risk Assessment in Chronic Coronary Disease" Out now in JACC Journals authors.elsevier.com/a/1hV-L2d9GHwV… 1/2

Multicenter, Prospective, RCT of hsTrop-I–Guided Combination #ARB and #BetaBlocker Therapy to Prevent #Anthracycline Cardiotoxicity: The Cardiac CARE Trial 📍 From Oct 2017-June 2021 on 175 patients (avg age 53, 87% female, 71% with breast cancer) 📍 No significant difference

Great to see Cardiac CARE Trial in print. Does high sensitivity troponin identify anthracycline treated patients who benefit from neurohormonal blockade?Grateful to trial participants and fantastic Cardiac CARE collaborators.#Cardioonc Ninian Lang Nicholas Mills International Cardio-Oncology Society

Presenting results of first dedicated pilot RCT to enrol patients with T2MI to CTCA guided treatment of coronary disease, funded by CSO. Successfully delivered with lots of lessons for the multi-centre trial. Paper out in JACC Journals in the next couple of days #ACC25